Project HOME, is one of the city's largest nonprofit housing agencies, serves 15,000 people a year. The group's head said that recent cutbacks have been “terrifying.” ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...

Abbott Laboratories ABT-1.10%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.04%increase; green up pointing triangle in a deal valued at about ...

On the call today are Chairman and Chief Technology Officer, Lawrence Ellison, Chief Executive Officer, Mike Cecilia, Chief ...

Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Abbot Laboratory has announced a deal to acquire Madison-based Exact Sciences for approximately $21 billion. Exact Sciences, known for its Cologuard cancer screening test, was founded in 1995 and ...

Investing.com -- Shares of Exact Sciences are soaring over 21% on Wednesday following a Bloomberg report that Abbott Laboratories is in advanced talks to acquire the medical-testing company. According ...

Abbott's acquisition of Exact Sciences aims to improve cancer diagnostics and expand access to early detection and management. Exact Sciences' products, including Cologuard and Oncotype DX, will ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...